Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027111 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Nuvig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07027111: Recruiting Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Nuvig Therapeutics.
NCT07027111 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Nuvig Therapeutics. The registered enrollment target is 60 participants, below the 155-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07027111, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Nuvig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Conditions Studied
Interventions
- DRUG NVG-2089
Study Locations (1)
Texas
- Nuvig Site - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-25 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT07027111 shows while recruiting
NCT07027111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 155-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which NVG-2089 is the first listed.
NCT07027111 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07027111 about?
NCT07027111 is a clinical study titled "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP". The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is ...
What is the current status of trial NCT07027111?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-04-25. Estimated completion is 2028-06-30.
What conditions does trial NCT07027111 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT07027111?
The interventions under investigation include: NVG-2089 (DRUG).
Who is sponsoring clinical trial NCT07027111?
This trial is sponsored by Nuvig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07027111 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07027111's enrollment target sits among peer trials
60 8th of 11 higher than 4 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 2
-
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI